ClinicalTrials.Veeva

Menu

Immune Monitoring of Hepatitis C Under DAA Therapy (IMHC)

U

University of Regensburg (UR)

Status

Unknown

Conditions

Hepatitis C

Study type

Observational

Funder types

Other

Identifiers

NCT02904603
IM-HC-1516

Details and patient eligibility

About

Direct acting antivirals offer a new opportunity to monitor the immune response in Hepatitis C infection. In this study cytokine markers will be measured during therapy up to time point SVR 12 an correlated to clinical Parameters and regular laboratory findings.

Enrollment

100 estimated patients

Sex

All

Ages

18 to 100 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • written consent, age, HCV-RNA positive, DAA therapy

Exclusion criteria

Trial contacts and locations

1

Loading...

Central trial contact

Georg Peschel; Kilian Weigand

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems